French pharmaceutical company BioAlliance Pharma is developing a new oral herpes treatment, Aciclovir Lauriad, which has just produced encouraging Phase III results.
The next step is to present these results to both European and American health authorities to see whether the drug can be licensed or whether further trials are necessary.
According to the response, BioAlliance Pharma will then be seeking a partner for the final development phase of the drug before its release, according to CEO Dominique Costantini. An existing agreement with Therabel, Belgium could see the latter providing up to 4 of funding in the next year.
